While Cipla’s relatively low sales growth is a dampener, the good showing on other fronts should comfort investors. But the pricing pressure in the US market has led to Cipla adjusting its research spending pattern. That shift is a nod to the fact that a slower-than-expected US market sales growth could lead to research as a proportion of sales to increase faster. The company’s US market sales grew by 2% to $100 million over a year ago and rose by 5% sequentially. While Cipla’s relatively low sales growth is a dampener, the good showing on other fronts should comfort investors.

Source: Mint February 08, 2018 02:15 UTC